| NAV | $9.68 | Daily Change | -$0.03 | -0.31% |
| Market Price | $9.64 | Daily Change | $0.04 | 0.42% |
The global telemedicine market increased over 8% from 2022 to 2023, exceeding $94bn. Forecasts suggest the market could reach over $286bn by 2028.1
AI could be the missing link to achieve transformative digitization in the Health Care sector. In the U.S. alone, it's estimated that AI could save as much as 10% of annual health care spending.2
Following success in diabetic monitoring, wearables are expanding into cardiovascular care. The potential market could be enormous, as an estimated 33mm people have atrial fibrillation3 and some 1.28bn adults have hypertension.4
1Fortune Business Insights, Jul 2023
2National Bureau of Economic Research, Jan 2023
3Frontiers in Public Health, Jun 2023
4World Health Organization, Mar 2023
| Inception Date | 07/29/20 |
| Total Expense Ratio | 0.68% |
| Net Assets | $41.70 million |
| NAV | $9.68 |
The Global X Telemedicine & Digital Health ETF (EDOC) seeks to invest in companies positioned to benefit from further advances in the field of telemedicine and digital health. This includes companies involved in Telemedicine, Health Care Analytics, Connected Health Care Devices, and Administrative Digitization.
The Global X Telemedicine & Digital Health ETF (EDOC) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Telemedicine & Digital Health Index.
| 30-Day SEC Yield | 0.33% |
| Distribution Frequency | Semi-Annually |
| NAV | $9.68 | Daily Change | -$0.03 | -0.31% |
| Market Price | $9.64 | Daily Change | $0.04 | 0.42% |
|
Cumulative Returns (as of 10/31/24)
|
1 Month | 6 Months | YTD | 12 Months | 24 Months | Since Inception | Inception Date |
|---|---|---|---|---|---|---|---|
| Return EDOC | -6.43% | 6.95% | -6.89% | 15.65% | -22.70% | -37.87% | 07/29/20 |
|
Returns (as of 11/19/24)
|
Return EDOC | Return Index |
|---|---|---|
| Since Inception | -36.22% | -34.92% |
| 12 Months | 8.53% | 9.09% |
| 24 Months | -20.65% | -20.06% |
| Last 60 Trading Days | 3.32% | 3.39% |
| Last 75 Trading Days | 11.01% | 11.07% |
|
Monthly Returns (through 11/19/24)
|
Return EDOC | Return Index |
|---|---|---|
| Nov 2024 | 2.65% | 2.67% |
| Oct 2024 | -6.43% | -6.40% |
| Sep 2024 | 6.88% | 6.96% |
| Aug 2024 | 3.39% | 3.33% |
| Jul 2024 | 3.98% | 4.05% |
| Jun 2024 | -2.96% | -2.94% |
| May 2024 | 2.50% | 2.59% |
| Apr 2024 | -7.32% | -7.26% |
| Mar 2024 | -0.02% | 0.06% |
| Feb 2024 | 1.91% | 1.92% |
| Jan 2024 | -7.79% | -7.67% |
| Dec 2023 | 13.52% | 13.51% |
| Nov 2023 | 9.42% | 9.52% |
| Oct 2023 | -10.99% | -11.00% |
| Sep 2023 | -11.21% | -11.15% |
| Aug 2023 | -13.97% | -13.91% |
| Jul 2023 | 3.18% | 3.21% |
| Jun 2023 | 4.66% | 4.70% |
| May 2023 | -5.45% | -5.40% |
| Apr 2023 | -0.09% | -0.03% |
| Mar 2023 | 0.33% | 0.40% |
| Feb 2023 | -6.01% | -6.31% |
| Jan 2023 | 7.01% | 7.03% |
| Dec 2022 | -4.53% | -4.47% |
| Nov 2022 | 4.52% | 4.60% |
Total returns take into account management, administration and fees and other costs automatically deducted from the fund's assets. Before investing, you may read the prospectus in the “FEES AND EXPENSES” section for more details.
| Net Assets (%) | Ticker | Name | Country | SEDOL | Market Price ($) | Shares Held | Market Value ($) |
|---|---|---|---|---|---|---|---|
| 4.90 | DOCS | DOXIMITY INC-CLASS A | United States | BMD22Y4 | 49.90 | 40,996 | 2,045,700.40 |
| 4.73 | MASI | MASIMO CORP | United States | B1YWR63 | 164.95 | 11,958 | 1,972,472.10 |
| 4.62 | PODD | INSULET CORP | United States | B1XGNW4 | 266.58 | 7,230 | 1,927,373.40 |
| 4.55 | PME AU | PRO MEDICUS LTD | Australia | 6292782 | 139.29 | 13,615 | 1,896,413.82 |
| 4.40 | LH | LABCORP HOLDINGS INC | United States | BSBK800 | 237.85 | 7,722 | 1,836,677.70 |
| 4.23 | DXCM | DEXCOM INC | United States | B0796X4 | 75.24 | 23,426 | 1,762,572.24 |
| 4.18 | DGX | QUEST DIAGNOSTICS INC | United States | 2702791 | 161.32 | 10,806 | 1,743,223.92 |
| 4.15 | HIMS | HIMS & HERS HEALTH INC | United States | BN46048 | 21.79 | 79,414 | 1,730,431.06 |
| 4.14 | RMD | RESMED INC | United States | 2732903 | 241.55 | 7,152 | 1,727,565.60 |
| 4.11 | 6618 HK | JD HEALTH | Hong Kong | BMW8R04 | 3.71 | 461,300 | 1,712,798.87 |
| 4.07 | QGEN | QIAGEN N.V. | United States | BMGBZP0 | 42.09 | 40,309 | 1,696,605.81 |
| 4.06 | VCYT | VERACYTE INC | United States | BFTWZY0 | 39.20 | 43,184 | 1,692,812.80 |
| 4.03 | OSCR | OSCAR HEALTH -A | United States | BKY83Q6 | 17.00 | 98,879 | 1,680,943.00 |
| 3.94 | A | AGILENT TECHNOLOGIES INC | United States | 2520153 | 128.57 | 12,763 | 1,640,938.91 |
| 3.75 | ILMN | ILLUMINA INC | United States | 2613990 | 131.68 | 11,877 | 1,563,963.36 |
| 3.47 | IQV | IQVIA HOLDINGS INC | United States | BDR73G1 | 194.38 | 7,436 | 1,445,409.68 |
| 3.39 | 241 HK | ALIBABA HEALTH | Hong Kong | BRXVS60 | 0.49 | 2,875,900 | 1,415,134.19 |
| 3.16 | TWST | TWIST BIOSCIENCE CORP | United States | BGKG6G7 | 41.11 | 32,013 | 1,316,054.43 |
| 3.10 | IRTC | IRHYTHM TECHNOLOGIES INC | United States | BYT4ST5 | 73.74 | 17,533 | 1,292,883.42 |
| 3.01 | PRVA | PRIVIA HEALTH GROUP INC | United States | BMDP209 | 20.79 | 60,433 | 1,256,402.07 |
| 2.68 | TNDM | TANDEM DIABETES CARE INC | United States | BF3W461 | 30.15 | 37,062 | 1,117,419.30 |
| 2.57 | OMCL | OMNICELL INC | United States | 2789523 | 41.82 | 25,607 | 1,070,884.74 |
| 2.08 | TDOC | TELADOC HEALTH INC | United States | BYQRFY1 | 9.00 | 96,165 | 865,485.00 |
| 1.71 | EVH | EVOLENT HEALTH INC - A | United States | BYLY8H1 | 11.31 | 63,105 | 713,717.55 |
| 1.49 | 1833 HK | PING AN HEALTHCA | Hong Kong | BDRYVB3 | 1.88 | 330,500 | 621,638.08 |
| 1.37 | PHR | PHREESIA INC | United States | BKF9DQ8 | 18.52 | 30,773 | 569,915.96 |
| 1.28 | AMN | AMN HEALTHCARE | United States | 2813552 | 24.80 | 21,510 | 533,448.00 |
| 1.10 | LFST | LIFESTANCE HEALT | United States | BN0TRB7 | 7.22 | 63,238 | 456,578.36 |
| 0.86 | 4483 JP | JMDC INC | Japan | BK7C5Q9 | 26.99 | 13,368 | 360,844.50 |
| 0.77 | 4480 JP | MEDLEY INC | Japan | BK93ZN7 | 27.51 | 11,713 | 322,193.13 |
| 0.61 | PACB | PACIFIC BIOSCIEN | United States | B4N8MH9 | 1.72 | 147,488 | 253,679.36 |
| 0.55 | TALK | TALKSPACE INC | United States | BP7L970 | 3.16 | 72,720 | 229,795.20 |
| 0.54 | COP GR | COMPUGROUP MEDIC | Germany | BMY7CH1 | 14.82 | 15,120 | 224,128.43 |
| 0.48 | GDRX | GOODRX HOLDIN-A | United States | BMTVQT8 | 4.31 | 46,146 | 198,889.26 |
| 0.46 | DCGO | DOCGO INC | United States | BKP4P23 | 4.10 | 47,270 | 193,807.00 |
| 0.46 | FLGT | FULGENT GENETICS INC | United States | BYQBFQ5 | 17.28 | 11,211 | 193,726.08 |
| 0.38 | LFMD | LIFEMD INC | United States | BMXDBQ2 | 5.42 | 28,830 | 156,258.60 |
| 0.28 | DH | DEFINITIVE HEALT | United States | BMGSDK2 | 4.10 | 28,369 | 116,312.90 |
| 0.28 | 228760 KS | GENOMICTREE INC | Republic Of Korea | BYNNYF6 | 11.36 | 10,117 | 114,912.19 |
| 0.08 | CASH | United States | 1.00 | 31,548 | 31,548.01 | ||
| 0.00 | OTHER PAYABLE & RECEIVABLES | United States | 1.00 | 1,142 | 1,141.88 | ||
| 0.00 | EURO | United States | 1.05 | 1 | 1.01 | ||
| 0.00 | HONG KONG DOLLAR | United States | 0.13 | 4 | 0.51 | ||
| 0.00 | TAIWAN DOLLAR | United States | 0.03 | 1 | 0.03 |
| Sector | Weight (%) | |
|---|---|---|
| Health Care | 92.4 | |
| Financials | 3.7 | |
| Materials | 3.6 | |
| Energy | 0.3 |
Source: AltaVista Research, LLC
| Country | Weight (%) | |
|---|---|---|
| United States | 84.4 | |
| China | 5.4 | |
| Netherlands | 4.0 | |
| Hong Kong | 3.7 | |
| Japan | 1.6 | |
| Germany | 0.6 | |
| South Korea | 0.3 |
Source: AltaVista Research, LLC
| Return on Equity | 4.20% | |
| Weighted Avg. Market Cap | 11,907 M | |
| 2023 | 2024 | |
| Price-to-earnings | 99.50 | 63.70 |
| Price-to-book value | 2.69 | 2.60 |
Source: AltaVista Research, LLC
| Versus | Beta |
|---|---|
| S&P 500 | 1.12 |
| MSCI EAFE | 1.14 |
| MSCI Emg. Mkts | 0.97 |
| Standard Deviation | 25.00% |
Source: AltaVista Research, LLC
TERMS OF USE
Global X Brasil Gestora de Investimentos Ltda. (“Global X Brasil”) is an asset manager authorized by the Brazilian Securities and Exchange Commission (“CVM”), constituted in the form of CVM Resolution No. 21/2021. Investing involves risks. The material on this site is for informational purposes only and does not constitute investment advice, recommendation, offer or solicitation to buy or sell any securities, funds, or strategies to any person in any jurisdiction in which an offer, solicitation, purchase, or sale would be illegal under the securities laws of such jurisdiction. Opinions expressed here are subject to change without notice. Reliance upon the information contained in this material is at the sole discretion of the reader. No securities regulator has confirmed the accuracy of any information contained herein. Access to the information on this site or the use of the services or information provided herein is prohibited by any person or entity in any jurisdiction or country where such distribution or use is contrary to local law, rules, or regulation. Investment in index funds (ETFs) involves risks, including detachment from the benchmark index and related to the liquidity of shares in the secondary market. Investment funds managed by Global X Brasil use strategies that can result in significant equity losses for their quota holders. Global X Brasil, its partners and employees are exempt of responsibility for any damages resulting directly or indirectly from the use of the information contained on this website.
FOR EVALUATION OF THE PERFORMANCE OF AN INVESTMENT FUND, IT IS RECOMMENDED THE ANALYSIS OF AT LEAST 12 (TWELVE) MONTHS. INVESTMENT FUNDS DO NOT HAVE A GUARANTEE FROM THE ADMINISTRATOR, THE MANAGER, ANY INSURANCE MECHANISM OR CREDIT GUARANTEE FUND – FGC. INVESTMENTS IN FINANCIAL AND CAPITAL MARKETS ARE SUBJECT TO RISKS OF LOSS GREATER THAN THE TOTAL VALUE OF INVESTED CAPITAL. PAST PROFITABILITY DOES NOT REPRESENT A GUARANTEE OF FUTURE PROFITABILITY THE PROFITABILITY DISCLOSED IS NOT NET OF TAXES. READ THE PROSPECTUS, THE FORM OF COMPLEMENTARY INFORMATION, SHEET OF ESSENTIAL INFORMATION AND THE REGULATION BEFORE INVESTING. DESCRIPTION OF THE ANBIMA TYPE AVAILABLE IN THE FORM OF COMPLEMENTARY INFORMATION.